Last updated: July 27, 2026
Vistide (cidofovir) is an older, off-patent antimetabolite antiviral administered under Risk Evaluation and Mitigation Strategy (REMS) conditions and restricted renal monitoring. Commercially, the drug is a niche product tied to specific indications and largely supported by continued clinical use and supply continuity rather than by late-stage pipeline expansion. No current, material phase 3 or registrational trial program is available in the public domain for new label expansion; clinical activity is primarily use-case, dosing optimization, and safety/renal monitoring in virology cohorts.
What clinical trials have been completed or updated for Vistide (cidofovir)?
Featured snippet: Public-facing clinical activity for Vistide is dominated by earlier registration-era studies and ongoing real-world evidence on renal safety, dosing strategies, and clinical use in CMV retinitis and related viral conditions. Current, new phase 3 registrational trials are not evident.
Which indications have Vistide trials historically supported?
Vistide is used for treatment of cytomegalovirus (CMV) retinitis in patients with AIDS when it is an approved indication in the U.S., and it has been studied across other DNA virus contexts in smaller cohorts.
Key historical clinical evidence themes:
- CMV retinitis response rates and durability
- Renal tubular toxicity risk and mitigation (hydration, probenecid coadministration, dose adjustments)
- Viral load and ocular disease control endpoints
- Long-term safety in immunocompromised populations
What is the current clinical-trials landscape (phase and intent)?
Featured snippet: The present-day footprint is mainly observational and optimization work, not a large late-stage development program.
Common contemporary study intents (when published in the literature):
- Renal safety profiling in real-world settings
- Modified dosing schedules to reduce nephrotoxicity risk
- Practical adherence to hydration and probenecid use
- Comparative effectiveness versus newer anti-CMV strategies where applicable
No publicly indexed evidence supports a current, FDA-facing phase 3 expansion effort for a new indication or a new delivery system that would materially shift the label.
How is Vistide (cidofovir) currently used clinically and what dosing/safety constraints drive demand?
Featured snippet: Vistide demand is constrained by nephrotoxicity management requirements and administration logistics, which reduce population-level scalability.
What renal toxicity mitigation requirements shape real-world use?
Across clinical practice, the dominant driver of usage friction is nephrotoxicity, typically managed using:
- Pre- and post-infusion hydration
- Coadministration of probenecid to reduce renal accumulation
- Frequent serum creatinine and urinalysis monitoring
- Dose holds or discontinuation for renal function decline
These controls influence:
- Clinician willingness to initiate therapy
- Treatment duration and dosing continuity
- Institutional formulary position
- Reimbursement and procurement stability
How does administration format affect utilization?
Vistide is administered as an infusion with preparation complexity tied to stability and handling requirements. This reduces convenience compared with some newer oral antivirals in adjacent viral spaces, limiting substitution unless clinical necessity is strong.
What is the Orange Book status of Vistide (cidofovir) and when do patents expire?
Featured snippet: Vistide is widely considered off-patent and exists in a small market with limited generic penetration in practical use contexts, with exclusivity history that does not support near-term brand-blocking.
A full Orange Book-driven table requires the specific NDC-to-patent mapping from FDA’s Orange Book. The topic request does not supply NDCs or the Orange Book listing record to anchor exact patent numbers and expiration dates. Without an extract of the relevant FDA listings, a complete and accurate expiration timeline cannot be produced.
How strong is the patent estate for Vistide (cidofovir) and what barriers do IP terms create for generics?
Featured snippet: IP barriers for Vistide are not evident as active late-expiring exclusivities that would block generic entry in the near term.
What types of patents would typically affect a small-molecule antiviral like cidofovir?
For older small-molecule antiviral products, any remaining protection typically falls into one or more categories:
- Composition-of-matter claims for cidofovir and/or salts and specific crystalline forms
- Process patents covering specific manufacturing steps or intermediates
- Formulation/handling patents (stability, concentration, diluent compatibility)
- Method-of-use claims (dosing regimens, coadministration strategies)
- New prodrugs or alternative delivery systems (rare for an established off-patent molecule)
What is the practical barrier profile in the market?
Even when patents are expired, market barriers can persist through:
- Low demand that discourages scale economics
- Quality system and sterile manufacturing capability
- Cost of renal monitoring protocols in practice
- Supply chain stability and allocation risk
- Reimbursement dynamics
For Vistide specifically, the market behaves more like a constrained-supply niche product than a protected blockbuster.
What generic entry risks exist for Vistide (cidofovir) and how likely is new competition?
Featured snippet: Generic entry risk is not the dominant factor; supply continuity, clinical protocol constraints, and market size determine availability.
Why generic competitive pressure may be limited
For niche antivirals, even with expired exclusivity:
- Pricing pressure can be insufficient to justify manufacturing and regulatory submissions.
- Distribution can be fragmented and institution-dependent.
- Drug procurement can remain brand-centric due to established handling protocols.
What timing matters for supply rather than IP
In practice, availability windows hinge on:
- Manufacturing outages
- Batch failures and sterility/assay compliance
- Regulatory inspection outcomes
- Contract manufacturing capacity
Those factors can create short-term “availability premiums” even absent IP.
What FDA regulatory status applies to Vistide (cidofovir) including REMS, labeling, and updates?
Featured snippet: Vistide is regulated as a prescription antiviral with safety constraints driven by nephrotoxicity and renal monitoring practices.
What labeling constraints matter for commercialization and institutional uptake?
Labeling typically drives:
- Renal function monitoring frequency
- Hydration requirements
- Concomitant probenecid use
- Dose modifications based on lab results
These constraints affect:
- Budget impact and procurement planning
- Nursing and infusion center throughput
- Clinical pathway inclusion in hospital protocols
How do FDA updates translate into market impacts?
Even minor label revisions can:
- Change administration protocol compliance requirements
- Trigger formulary review cycles
- Influence patient selection criteria
No current request inputs provide an FDA label revision log, so a specific “latest labeling date” and content-change list cannot be produced here.
How does Vistide (cidofovir) compare with alternative CMV therapies in clinical use and market position?
Featured snippet: In CMV retinitis and related CMV disease contexts, Vistide competes primarily against alternative anti-CMV options where available and clinically appropriate, with substitution limited by toxicity profiles and renal safety considerations.
Comparison dimensions that drive switching
Switching from Vistide is driven by:
- Renal toxicity burden relative to alternatives
- Route of administration convenience
- Monitoring requirements
- Drug-drug interaction profile
- Evidence strength for ocular disease control
- Formulary preference based on institution protocols
Market implication
Vistide’s market is influenced less by pricing and more by:
- Clinical necessity
- Availability
- Provider comfort with renal mitigation workflows
What is the commercial size of Vistide (cidofovir), and what revenue projection model is appropriate?
Featured snippet: Vistide revenue is best modeled as a niche, protocol-driven annual demand curve with supply-availability shocks, not as a growth story.
Projection approach for a niche antiviral
A practical projection framework for Vistide uses:
- Indication-driven demand (CMV retinitis cohort size and treatment incidence)
- Protocol adherence and substitution rates (how often clinicians choose alternatives)
- Supply continuity factor (stockouts and manufacturing interruptions)
- Pricing and reimbursement (net price trends for specialty hospital products)
- Utilization shift (oncology/HSCT/other off-label channels where clinicians use it and whether those channels tighten)
What can and cannot be quantified from the prompt
The request asks for “market analysis and projection.” The prompt does not provide:
- Historical sales by year
- Current manufacturer and distributor network
- NDC-level pricing or net revenue
- Supply status or unit availability
- Indication incidence estimates for the relevant treated population
Without those inputs, providing a quantified revenue forecast (numbers, CAGR, or year-by-year projections) would be speculative.
Key operational risks for Vistide (cidofovir) supply and commercialization
Featured snippet: The largest foreseeable risks are supply continuity and renal-safety protocol burden, which directly affect treated volume.
- Manufacturing and supply volatility
- Clinician and patient risk tolerance around nephrotoxicity
- Institutional protocol inclusion
- Substitution by alternative CMV therapies when clinically feasible
- Budget and reimbursement constraints for specialty infusion products
Key Takeaways
- Vistide’s clinical and market profile is niche and protocol-driven, dominated by CMV disease use cases and renal toxicity management requirements.
- Publicly visible development activity appears limited to clinical optimization and real-world safety work rather than new large registrational trials.
- IP-driven exclusivity is not the main near-term determinant of competition; supply continuity and clinical workflow constraints are more decisive.
- A quantified revenue projection cannot be generated from the information provided in the prompt; any numerical forecast would be speculative.
FAQs
- Is Vistide (cidofovir) still used for CMV retinitis in current clinical practice?
- What renal monitoring regimen is typically required when patients receive Vistide?
- How do Vistide’s nephrotoxicity risks influence hospital formulary decisions?
- Are there any active phase 3 clinical trials for cidofovir or Vistide label expansion?
- What are the most common reasons for treatment discontinuation or dose adjustment with Vistide?
References (APA)
- FDA Orange Book. Application(s) and Drug(s) with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Source not extractable from provided prompt.)
- FDA. Vistide (cidofovir) prescribing information. U.S. Food and Drug Administration. (Specific version/date not provided in prompt.)
- PubMed. Cidofovir clinical trials and real-world studies in CMV retinitis. National Library of Medicine. (No specific study list provided in prompt.)
